Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
IRVINE, Calif., Sept. 1, 2005 (PRIMEZONE) -- The informational report "Homeland Defense and the Market" has been made available free of charge at www.SmallCapSentinel.com and will address the rise of...
-
IRVINE, Calif., Aug. 31, 2005 (PRIMEZONE) -- The informational report "ANALYST NOTES: Technology Growth, Emerging Companies & Emerging Markets" has been made available free of charge at...
-
IRVINE, Calif., Aug. 30, 2005 (PRIMEZONE) -- The informational report "Innovations in Biotechnology" has been made available free of charge at www.SmallCapSentinel.com and will address stents and...
-
IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "While many fear the lack of investment dollars in the stock market by retiring baby boomers, savvy investors are focusing on the areas where this...
-
IRVINE, Calif., Aug. 29, 2005 (PRIMEZONE) -- "Guidant Corporation's (NYSE:GDT) announcement that the company has received Phase II approval from the Food and Drug Administration (FDA) to expand...
-
IRVINE, Calif., Aug. 25, 2005 (PRIMEZONE) -- "Investors would be wise to note that some of the greatest innovations come from the ranks of smaller, lesser-followed companies. The absence of multiple...
-
IRVINE, Calif., Aug. 25, 2005 (PRIMEZONE) -- "With national security an omnipresent concern, it appears that often the only difference between local law enforcement activity and anti-terrorism...
-
IRVINE, Calif., Aug. 24, 2005 (PRIMEZONE) -- A report detailing the opportunities for emergent technologies in today's stock market has been made available at SmallCapSentinel.com. The report,...
-
IRVINE, Calif., Aug. 23, 2005 (PRIMEZONE) -- A report detailing the opportunities for emergent technologies in today's stock market has been made available at SmallCapSentinel.com. The report,...
-
IRVINE, Calif., Aug. 23, 2005 (PRIMEZONE) -- "The recent ruling against Merck (NYSE:MRK) further amplifies the biotechnology and pharmaceutical industry's insatiable appetite for new products,"...